Molybdenum cofactor deficiency (MoCD) is a lethal autosomal recessive inborn error of metabolism with devastating neurologic manifestations. Currently, experimental treatment with cyclic pyranopterin monophosphate (cPMP) is available for patients with MoCD type A caused by a mutation in the MOCS-1 gene. Here we report the first case of an infant, prenatally diagnosed with MoCD type A, whom we started on treatment with cPMP 4 hours after birth. The most reliable method to evaluate neurologic functioning in early infancy is to assess the quality of general movements (GMs) and fidgety movements (FMs) . After a brief period of seizures and cramped-synchronized GMs on the first day, our patient showed no further clinical signs of neurologic deterioration. Her quality of GMs was normal by the end of the first week. Rapid improvement of GM quality together with normal FMs at 3 months is highly predictive of normal neurologic outcome. We demonstrated that a daily cPMP dose of even 80 mg/kg in the first 12 days reduced the effects of neurodegenerative damage even when seizures and cramped-synchronized GMs were already present. We strongly recommend starting cPMP treatment as soon as possible after birth in infants diagnosed with MoCD type A. Molybdenum cofactor deficiency (MoCD) is a rare inherited metabolic disorder leading to a combined deficiency of sulfite oxidase, xanthine dehydrogenase, and aldehyde oxidase, 1 as well as amidoxime. 2 The accumulation of sulfite due to lack of sulfite oxidase probably causes progressive neurologic damage and death in early infancy. 3 Type A is most common (Fig 1) and occurs in approximately two-thirds of patients. Life-long intravenous administration of the missing substance, cyclic pyranopterin monophosphate (cPMP), is a potentially effective treatment strategy for these patients. In the first treated patient, cPMP substitution commenced 36 days after birth. 4 Despite the initial promising results, the patient developed signs of quadriplegic cerebral palsy at 18 months. Therefore, starting treatment as soon as possible after birth is of utmost importance. 5 Over the years, attention has been drawn increasingly to the need for early identification of infants at risk for neurologic impairment. The most reliable method to evaluate neurologic functioning up to 5 months after term is the assessment of the quality of general movements (GMs) from video recordings. 6, 7 Normal GMs are complex and variable, whereas abnormal GMs appear monotonous with reduced complexity and variability. 7 At ∼3 months, GMs acquire a fidgety character (ie, continuous small movements of moderate speed in all directions). The quality of these fidgety movements (FMs), normally present between 9 and 20 weeks after term, is a particularly accurate marker for neurologic deficits: most infants (96%) with normal FMs have normal neurologic outcomes, whereas most infants (95%) in whom FMs are absent during this period develop cerebral palsy. 8 We report here on the neurodevelopmental outcome of a patient, diagnosed prenatally with MoCD type A, in whom experimental treatment with cPMP commenced 4 hours after birth.
PATIENT PRESENTATION Clinical Presentation
Our patient was the fifth child of healthy, white, nonconsanguineous parents. They had 2 healthy boys, but their 2 girls both presented with seizures on day 1 and died shortly afterwards. The first girl was thought to have had either sepsis or congenital heart disease, whereas in the second girl, urine levels of sulfite, sulfocysteine, xanthine, and hypoxanthine were elevated and compound Z (cPMP oxidation product) was absent without cPMP being detected. Subsequent DNA analysis revealed homozygosity for the 418+1G.A mutation in the MOCS-1 gene, proving MoCD type A deficiency.
In the infant described here, prenatal diagnosis was based on DNA assessment. Birth was induced at 36+3 weeks of gestation: the potential benefits of early treatment outweighing the risks of prematurity. After an uncomplicated delivery, a hypo-active girl was born revealing low muscle tone and hyperreflexia (birth weight: 3235 g; Apgar 8/8 at 1 and 5 minutes). Because of low pulse oxygen saturation and hypotension, she required continuous positive airway pressure, oxygen, and repeated saline infusions and dopamine up to 12 hours after birth.
Dosing Schedule and Intravenous Administration of cPMP
After parental consent and approval by the review board, experimental treatment with cPMP commenced 4 hours afterbirth (seedosingscheduleinTable 1).
In the absence of detailed dose finding and safety studies, cPMP was increased to 160 mg/kg per day on day 35 following the treatment schedule of the first patient. 4 Given the excellent tolerability of 240 mg/kg per day in the initial patient (oral communication), cPMP was increased to 240 mg/kg per day to achieve lowest possible SSC levels. After discharge (10 weeks), cPMP infusion was continued once daily by the parents per central venous access.
Metabolic Investigations
Within 2 days after birth, sulfite dipstick test results became negative and remained so. Within days 2 to 9,
FIGURE 1
Schematic presentation of molybdenum cofactor biosynthesis in humans. According to subsequent steps in the metabolic pathway, 3 subtypes of MoCD can be distinguished: type A, B, and C involving genetic mutations in MOSC-1, MOSC-2, and MOSC-3, respectively. cPMP, cyclic pyranopterin monophosphate; GTP, guanosine triphosphate; MPT, molybdopterin. 3 A, EEG (third row) and aEEG patterns registered with the CFM Olympic 6000 (Natus Medical Incorporated, San Carlos, CA) revealing 2 single seizures at 21 hours after birth. The scale on the y axis is semilogarithmical, ie, linear from 0 to 10 mV, and logarithmical from 10 to 100 mV. The x axis represents time, a 10-minute period on the aEEG and a 1-second period on the EEG indicated by the horizontal arrows. B, aEEG pattern revealing a continuous normal voltage pattern with sleep-wake cycling without any seizures at 14 hours after birth. The scale on the y axis is semilogarithmical, ie, linear from 0 to 10 mV, and logarithmical from 10 to 100 mV. The x axis represents time, a 10-minute period indicated by the horizontal arrows.
seizures (Fig 2A) . This was consistent with standard EEG that displayed multiform epileptiform discharges on day 1. Sleep-wake cycling was present from 14 hours after birth onwards (Fig 2B) .
Assessment of GMs From Birth Until 18 Weeks After Term
Video recordings were made daily on days 1 to 8, days 10, 16, 23 Figure 3 depicts the results on the quality of GMs. Two recordings were discarded due to crying (days 10 and 28). On the first day, just before cPMP infusion commenced, we observed cramped-synchronized GMs with an MOS of 8 points. Although GMs were still labeled abnormal (poor repertoire) on the second day, there was an improvement in MOS to 9 points after the fourth cPMP dose. The quality of GMs became normal after the 11th dose at
FIGURE 3
A, Uric acid blood levels and B, urinary S-Sulfocysteine levels (SSC) in relation to the change in quality of GMs and MOS at postnatal days 1 to 8 (measurements 1-8), 16 (measurement 9) and 23 (measurement 10). Stars represent cramped-synchronized GMs, triangles poor repertoire GMs, and round symbols normal GMs. day 6. At days 118 and 153, we observed normal FMs with an MOS of 26 points (not shown).
Neurodevelopmental Course Up to 21 Months' Corrected Age
Follow-up at 26 weeks revealed dystonia (variable hypo-and hypertonia) with a continuously present tremor, which both improved during the next 6 months. At 21 months' corrected age, we performed the Bayley Scales of Infant and Toddler Development, Third Edition. 13 Data are shown in Table 2 . At this age, no tremors were observed anymore. Behavioral outcome, evaluated by the Child Behavior Checklist 1.5 to 5 years, 14 revealed no behavioral problems.
DISCUSSION
This case report demonstrates favorable outcome, based on aEEG and GMs, in MoCD type A, in response to experimental cPMP treatment administered daily from the first day after birth.
Given the lack of drug-related adverse events at high cPMP doses (both in our and the previous case), the mild respiratory problems and hypotensive episodes during the first hours after birth might be related to transitional problems (due to elective late preterm birth) rather than to cPMP infusions. 15 Neurologic features of surviving MoCD type A children generally resemble those of ischemic brain injury and involve epilepsy, abnormal muscle tone, microcephaly, and lens dislocation. 1 Accordingly, our patient presented with a brief period of clinical seizures before cPMP initiation. After commencing cPMP treatment, however, the aEEG background pattern normalized and clinical seizures dissolved. Sleep-wake cycling emerged as early as 14 hours after birth. In term asphyxiated infants, both improvement of aEEG patterns within 24 hours after birth and the onset of sleep-wake cycling within 36 hours are recognized as good prognostic indicators of normal outcome. 16, 17 In accordance with previous preterm studies, 11, 18 we observed slight fluctuations in GM quality and MOS during the first week. Scaled scores for cognitive, gross, and fine motor outcome, as well as the cognitive and total motor composite scores were calculated corrected for preterm birth. Based on the scaled scores and the composite scores (mean: 10 [SD: 3] and 100 [SD: 15] , respectively), the infant was classified as normal (,1 SD below the mean), mildly delayed (1-2 SD below the mean), or abnormal (.2 SD below the mean).
